STAT+: Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.